4 ms·
We already have some major issues with drug efficacy (and maybe safety) in certain populations. This is because the vast majority of drugs are only tested on 2
by LatteLazy 4y ago
We already have some major issues with drug efficacy (and maybe safety) in certain populations. This is because the vast majority of drugs are only tested on 20-something males, (usually white middle class ones, college attending, otherwise healthy ones). I wonder how that issue will be impacted by further reducing other forms of testing. And I wonder if this will make drug testing more difficult to recruit for (asking someone to try a new drug that has been tested in animals vs one that has not).
- isitmadeofglass 4y ago[dead]
- vibrio 4y agoI'm not sure how to interpret 'the vast majority of drugs' as it is a pretty broad brush including everything from over the counter itch creams to genetically engineered cell therapies. For the subset of "cancer therapy drugs" I would guess that demographic bias does not hold, as first in human is generally people who have had all available drugs fail them and are often considering toxic chemotherapy or palliation. recruiting there is generally easier. I hope that elimination of animal data doesn't decrease safety- there are flaws in animal models and use for sure.